• Bismuth Subsalicylate: Precision Tools for GI Disorder Resea

  2026-06-18

  Bismuth Subsalicylate, as 1,3,2λ2-benzodioxabismin-4-one, empowers cutting-edge gastrointestinal disorder research by targeting inflammation pathways with high reproducibility. This article unpacks advanced workflows, protocol refinements, and troubleshooting strategies—translating bench insights into robust, actionable research outcomes.

• Intra- and Extracellular Dicloxacillin Activity Against MSSA

  2026-06-18

  This review analyzes a pivotal study examining the intra- and extracellular efficacy of dicloxacillin against methicillin-sensitive Staphylococcus aureus (MSSA) using both in vitro macrophage and in vivo mouse peritonitis models. The work clarifies the pharmacodynamic predictors of therapeutic success and highlights the relevance of MIC as an indicator for both cellular compartments, offering guidance for translational Gram-positive infection research.

• Sulfaphenazole: Mechanistic Insights for Vascular Research

  2026-06-17

  Explore Sulfaphenazole's role as a CYP2C9 inhibitor and its unique impact on vascular endothelial function and oxidative stress reduction. This article offers an in-depth scientific perspective, bridging foundational mechanisms with translational assay design.

• Human iPSC-Derived Sensory Neurons Model HSV-1 Latency and R

  2026-06-17

  This study establishes a scalable human sensory neuron model derived from inducible pluripotent stem cells for investigating herpes simplex virus 1 (HSV-1) latency and reactivation. The work bridges a critical gap between animal models and human neurovirology, enabling direct study of neuron-intrinsic mechanisms relevant to persistent viral infection and therapeutic research.

• SU 5402: Advanced Inhibitor Strategies in Multimodal Cancer

  2026-06-16

  Explore the scientific depth of SU 5402, a potent receptor tyrosine kinase inhibitor, in dissecting cell signaling and apoptosis in multiple myeloma and beyond. This article provides unique insights into its advanced applications, bridging molecular oncology and innovative assay models.

• SMAD3 Inhibition Reduces ADAMTS-5 in Early Osteoarthritis Mo

  2026-06-16

  Xiang et al. demonstrate that selective inhibition of SMAD3, particularly using SIS3, suppresses ADAMTS-5 expression in early-stage osteoarthritis via upregulation of miRNA-140. These mechanistic insights highlight the TGF-β/Smad3 axis as a promising target for modifying cartilage degradation and advancing preclinical fibrosis research.

• PA-824: Advancing Dual-Target Tuberculosis Research Strategi

  2026-06-15

  This thought-leadership article explores the mechanistic and translational frontiers of PA-824, a bicyclic nitroimidazole derivative with potent dual-action bactericidal activity against Mycobacterium tuberculosis. By integrating the latest mechanistic insights, experimental design guidance, and strategic perspectives, we illuminate how PA-824 is reshaping tuberculosis research, especially for drug-resistant strains. This piece distinguishes itself from standard product content by bridging the molecular rationale with emerging combination regimens and workflow optimization, offering actionable pathways for translational researchers.

• Serine/Glycine-Free Diet Enhances Immunity and PD-L1 Evasion

  2026-06-15

  Tong et al. (2024) reveal that a serine/glycine-free diet inhibits colorectal cancer growth by boosting cytotoxic T cell immunity, but also uncovers a new immune evasion pathway via PD-L1 lactylation. This dual effect suggests that dietary interventions may synergize with immunotherapy, though care must be taken regarding potential resistance mechanisms.

• Acetoacetic Acid Sodium Salt: Molecular Insights for Advance

  2026-06-14

  Explore how acetoacetic acid sodium salt enables mechanistic and translational breakthroughs in diabetes metabolic imbalance. This article delivers a molecular perspective and advanced protocol guidance that surpasses typical workflow-focused resources.

• Chenodeoxycholic Acid in FXR Research: Protocols & Renal Pro

  2026-06-13

  Chenodeoxycholic Acid (CDCA) unlocks translational studies of nuclear receptor signaling, providing rigorous control over FXR-mediated pathways in cholesterol metabolism and acute kidney injury models. This guide details validated experimental workflows, troubleshooting strategies, and the latest mechanistic insights that position CDCA as a keystone reagent for high-impact metabolic and renal research.

• PA-824: Bicyclic Nitroimidazole Derivative for TB Research

  2026-06-12

  PA-824 stands out as a dual-action bicyclic nitroimidazole derivative with proven efficacy against both replicating and non-replicating Mycobacterium tuberculosis, including drug-resistant strains. This guide translates cutting-edge mechanisms and recent synergy data into practical workflows and troubleshooting tips for high-impact tuberculosis research.

• Mitomycin C: Antitumor Antibiotic Workflows in Cancer Resear

  2026-06-12

  Mitomycin C sets the benchmark for apoptosis signaling and DNA replication inhibition in advanced cancer model systems. This guide details applied workflows, troubleshooting, and the latest insights—from centromeric transcription regulation to combinatorial protocols—enabling researchers to maximize reproducibility and mechanistic depth.

• Structure-Based Screening Identifies NSP15 Inhibitors for SA

  2026-06-11

  This study presents a virtual screening and molecular dynamics approach to identify natural product inhibitors against NSP15, a SARS-CoV-2 endoribonuclease involved in immune evasion. Thymopentin and oleuropein emerged as potent candidates, with stable binding and potential to reduce viral virulence, laying groundwork for targeted COVID-19 therapeutic development.

• Optimized hiPSC Platelet Differentiation via Small Molecules

  2026-06-11

  This study presents a refined, cost-effective protocol for differentiating functional platelets from human induced pluripotent stem cells by integrating small molecule modulators and optimized culture conditions. The innovation significantly improves platelet yield, reduces production time, and demonstrates translational potential for platelet biomanufacturing.

• CDCA and FXR-KLF11 Axis: New Horizons in Translational Kidne

  2026-06-10

  Chenodeoxycholic Acid (CDCA), a potent FXR agonist, is revolutionizing our understanding and strategic approach to renal protection in contrast-induced acute kidney injury (CI-AKI). This article offers translational researchers a mechanistic deep dive into the FXR-KLF11-JAK2/STAT3 pathway, a synthesis of recent experimental advances, and actionable guidance for leveraging CDCA in preclinical and clinical contexts.

8490 records 8/566 page Previous Next First page 上5页 678910 下5页 Last page